Research Topics
Species | Peter C EnzingerSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Impact of hospital volume on recurrence and survival after surgery for gastric cancerPeter C Enzinger
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Ann Surg 245:426-34. 2007..However, because such data may be significantly influenced by the impact of postoperative mortality, and may be imbalanced for factors important to survival, the true nature of this relationship remains uncertain...
A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinomaPeter C Enzinger
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Dig Dis Sci 50:2218-23. 2005..When used as a single-agent, a tri-weekly schedule may be preferable for this patient population...- Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancerP C Enzinger
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Ann Oncol 20:475-80. 2009..Recent studies have examined the addition of docetaxel to fluorouracil and cisplatin in advanced esophagogastric cancer... - Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancerJeffrey A Meyerhardt
Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 24:1892-7. 2006..To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer... - CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinomaShuji Ogino
Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
Virchows Arch 450:529-37. 2007..Additional studies are necessary to examine the role of DNA methylation in treatment efficacy... - Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancerMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 25:4787-92. 2007..We evaluated an oral regimen of capecitabine and erlotinib in patients with advanced pancreatic cancer who had experienced treatment failure with standard first-line therapy with gemcitabine... - Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancerBrian M Wolpin
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Clin Colorectal Cancer 6:208-13. 2006.... - Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904Matthew H Kulke
Dana Farber Cancer Institute, Boston, MA, USA
J Clin Oncol 27:5506-12. 2009..We explored the efficacy and toxicity of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in a multi-institutional, randomized, phase II study... - A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumorsMatthew H Kulke
Department of Medical Oncology, Dana Institute, Boston, Massachusetts, USA
Dig Dis Sci 51:1033-8. 2006..4 months. We conclude that while the combination of irinotecan and cisplatin may have activity in aggressive neuroendocrine tumor subtypes, this combination is inactive in patients with well-differentiated neuroendocrine tumors... - Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancerJeffrey A Meyerhardt
Dana Farber Cancer Institute, Brigham Women s Hospital, Boston, MA 02115, USA
Clin Colorectal Cancer 6:59-65. 2006..Whether these results apply to other cancer types is unknown but worthy of further study... - Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancerJeffrey A Meyerhardt
Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer Chemother Pharmacol 60:661-70. 2007.... - Phase 2 study of cetuximab in patients with advanced hepatocellular carcinomaAndrew X Zhu
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
Cancer 110:581-9. 2007..A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC... - A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagusMatthew H Kulke
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Cancer Invest 24:229-34. 2006..Our findings therefore support the continued use of epirubicin rather than doxorubicin in combination chemotherapy regimens for advanced gastroesophageal cancer... - Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerJeffrey A Meyerhardt
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
PLoS ONE 7:e38231. 2012..To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer... 
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumorsJennifer A Chan
Dana Farber Cancer Institute, Boston, MA 02215, USA
J Clin Oncol 30:2963-8. 2012..We performed a phase II study to evaluate the efficacy of temozolomide in combination with bevacizumab in patients with locally advanced or metastatic NETs...- A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancerJason E Faris
Department of Medical Oncology, Massachusetts General Hospital Cancer Center, POB 221, Boston, MA 02114, USA
Invest New Drugs 30:1614-20. 2012..MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin-β family. We conducted an open-label Phase II study with MKC-1 in patients with advanced pancreatic cancer... - Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumorsMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 24:401-6. 2006..We evaluated the efficacy of an oral regimen of temozolomide and thalidomide in patients with metastatic carcinoid, pheochromocytoma, or pancreatic neuroendocrine tumors... - O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumorsMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Clin Cancer Res 15:338-45. 2009..We evaluated the prevalence of MGMT deficiency in neuroendocrine tumors and correlated MGMT deficiency with treatment response to temozolomide-based regimens... - Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinomaAndrew X Zhu
Massachusetts General Hospital, Boston, MA, USA
J Clin Oncol 24:1898-903. 2006.... - Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
Lancet Oncol 11:48-54. 2010.... - A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinomaMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Invest 24:346-50. 2006..9 months and the median overall survival time was 7.8 months. We conclude that vinorelbine has minimal toxicity but only minor antitumor activity in patients with advanced gastroesophageal adenocarcinoma... - Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancerAndrew X Zhu
Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
Cancer Chemother Pharmacol 59:285-93. 2007.... - Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancerBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 27:193-8. 2009..We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor of mTOR, in patients who experienced treatment failure on first-line therapy with gemcitabine... - A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancerDavid P Ryan
Dana Farber Partners Cancer Care Gastrointestinal Cancer Center, Brigham and Women s Hospital, Dana Farber Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, USA
Cancer Invest 21:505-11. 2003.... - Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumorsMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 24:3555-61. 2006..We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors... - Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancerShuji Ogino
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Clin Cancer Res 11:6650-6. 2005..Abnormalities of EGFR and related pathways may have an effect on responsiveness of advanced colorectal cancer to combination chemotherapy with gefitinib... - Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal CancerBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Oncologist 18:377-8. 2013..2% vs. 29.4%) and longer OS times (10.6 vs. 3.7 months). Conclusions. The oral combination of tivozanib and everolimus was well tolerated, with stable disease achieved in 50% of patients with refractory, metastatic colorectal cancer... - Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumorsDavid P Ryan
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer 107:2482-9. 2006..The effect of gemcitabine on proteasome inhibition by bortezomib in whole blood was also investigated... - Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapyJeffrey A Meyerhardt
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 23:8453-60. 2005..Although several comprehensive dietary questionnaires have been validated and calibrated in healthy populations, similar studies have not been performed among cancer patients... - Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu
Division of Hematology Oncology, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Oncol 27:3027-35. 2009..To assess the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) and explore biomarkers for sunitinib response... - A Phase II trial of gemcitabine for metastatic neuroendocrine tumorsMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer 101:934-9. 2004..Gemcitabine is generally well tolerated and possesses demonstrated activity against a wide range of malignancies. The authors assessed the efficacy of gemcitabine in the treatment of patients with metastatic neuroendocrine tumors... - Gastrointestinal cancer in older patientsPeter C Enzinger
Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Semin Oncol 31:206-19. 2004..There is a paucity of information concerning the treatment of elderly patients with other gastrointestinal malignancies... - Esophageal cancerPeter C Enzinger
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
N Engl J Med 349:2241-52. 2003 - Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesisAustin M Dulak
Departments of Medical Oncology, Cancer Biology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA 02215, USA
Cancer Res 72:4383-93. 2012..Together, our results defined genomic features that were common and distinct to various gut-derived adenocarcinomas, potentially informing novel opportunities for targeted therapeutic interventions... - The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancerA David McCollum
Texas Oncology, PA, and Baylor Sammons Cancer Center, Dallas, TX 75246, USA
Am J Clin Oncol 29:40-4. 2006..We conducted a multicenter, phase II study to examine the combination of capecitabine and thalidomide (Cape/Thal) in patients with refractory metastatic CRC... - Should people with Barrett's esophagus, who are at risk for cancer of the esophagus, avoid alcohol?Peter C Enzinger
Health News 10:16. 2004